Table 2.
Glutamine metabolism‐related markers in relation to clinicopathological characteristics and EGFR mutation status. Glutamine transporter SLC1A5 protein expression is higher in adenocarcinomas with a worse pTNM stage
| SLC1A5 | ||||
|---|---|---|---|---|
| <5% | 5–20% | >20% | P‐value | |
| pTNM stage | ||||
| Stage I | 17 (65.4%) | 2 (7.7%) | 7 (26.9%) | P = 0.009 |
| Stage II | 1 (11.1%) | 7 (77.8%) | 1 (11.1%) | |
| Stage III | 0 (0%) | 2 (28.6%) | 5 (71.4%) | |
| Stage IV | 1 (100%) | 0 (0%) | 0 (0%) | |
Two tissue samples were missing for adenocarcinomas, resulting in 43 adenocarcinomas.
SLC1A5, Solute carrier family 1 (neutral amino acid transporter) member 5.